肿瘤坏死因子拮抗剂在治疗非银屑病性皮肤病中的临床应用

China Journal of Leprosy and Skin Diseases ›› 2018, Vol. 34 ›› Issue (11): 698-700，704.

Previous Articles Next Articles

Update of tumor necrosis factor inhibitor for the treatment of non-psoriatic skin diseases

罗玲玲，崔盘根

Institute of Dermatology,Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China

Online:2018-11-15 Published:2018-12-02
Contact: CUI Pangen, E-mail: cuipangen@126.com

Abstract

Abstract: Inhibition of tumor necrosis factor (TNF) plays an important role in anti-inflammation through blocking the binding of TNF and receptors to suppressing the activation of inflammatory factors, transmission of intracellular signals and cell proliferation. The common TNF inhibitors including infliximab (IFX), etanercept (ENT) and adalimumab (ADA) have widely being used in the treatment of non-psoriatic skin diseases, which is reviewed in this paper.

Key words: tumor necrosis factor, inhibitor, skin diseases besides psoriasis

LUO Lingling, CUI Pangen. Update of tumor necrosis factor inhibitor for the treatment of non-psoriatic skin diseases [J].China Journal of Leprosy and Skin Diseases, 2018, 34(11): 698-700，704.

[1]	CHE Xuanlin, SU Juan, CHEN Mingliang. Acquired hemophilia associated with bullous pemphigus: a case report [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(2): 110-111.
[2]	ZHOU Yanjun, WANG Ying, LIU Xiaoqin, LI Fengxiang, YANG Xiaolong, XIONG Xincai. Acneiform drug eruption caused by afatinib: two cases report [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(2): 116-118.
[3]	LIU Yunyi, JIANG Peiyu, LI Min, TAO Meng, LIU Yixuan, ZHANG Jiawen, NAN Yuqing, XU Yang. Cutaneous adverse effects of immune-checkpoint inhibitors [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(2): 135-138.
[4]	HE Zhendan, XIAO Yizhu. Clinic analysis of 75 chiliren with severe drug eruption [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(9): 561-564.
[5]	LU Wenhua, GUO Jia, CAO Duling, ZHU Wu. Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion protein with glucocorticoid successfully treat Stevens-Johnson syndrome: a case report [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(8): 525-527.
[6]	WANG Ziwei, LUAN Chao, HU Yu, JU Mei. Advances in the targeted therapy of vitiligo [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(7): 477-480.
[7]	GAO Yingli, LI Yuzhen. Advances in the treatment of psoriatic arthritis by tofacitinib [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(6): 402-405.
[8]	LIU Wanwen, GUO Meiliang, MENG Qinqin, YUAN Dingfen, DENG Hui. Update of JAK inhibitors in the therapy of psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(10): 684-688.
[9]	HE Chunxia, SI Xiaoyan, QU Tao, ZHANG Li. Psoriasis induced by immune checkpoint inhibitor pembrolizumab: a case report and literature review [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(1): 3-7.
[10]	WANG Meiling, LIU Huaxu. Update of the pathogenesis and therapeutic mechanism of port wine stain [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(9): 564-567.
[11]	YUE Wanbo, XU Qianyue, YU Hong. Mastocytosis: pathogenesis and treatment [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(8): 505-508.
[12]	LI Ming, ZHOU Boyang, LI Linfeng. Cutaneous adverse reactions of PD-1/PD-L1 inhibitors [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(8): 509-512.
[13]	SI Haipeng, GAO Lili, WANG Jianrong. Expression of matrix metalloproteinase-12 and its tissue inhibitor-1 in the lesions of BCC and SCC [J]. China Journal of Leprosy and Skin Diseases, 2018, 34(8): 457-459,463.
[14]	WANG Xiaopeng, WU Xiujuan, ZHAO Zongfeng, WANG Peng , YAKEYA.Buwajieer, PU Xiongming , KANG Xiaojing. Association of single nucleotide polymorphism of TNF-α and vitiligo in the patients of Uygur nationality in China [J]. China Journal of Leprosy and Skin Diseases, 2018, 34(7): 403-406.
[15]	CHU Xiaoyan, LU Guiqing, BI Zhigang.. Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein for the treatment of impetigo herpetiformis: a case report and literature review [J]. China Journal of Leprosy and Skin Diseases, 2017, 33(10): 596-598.

Update of tumor necrosis factor inhibitor for the treatment of non-psoriatic skin diseases

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10